UK markets closed

OPGEN INC OPGEN ORD SHS (0A8L.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
0.5142-0.0192 (-3.61%)
At close: 04:03PM BST
Full screen
Previous close0.5334
Open0.5142
BidN/A x N/A
AskN/A x N/A
Day's range0.5142 - 0.5142
52-week range0.2468 - 0.7800
Volume200
Avg. volume5,921
Market capN/A
Beta (5Y monthly)-0.69
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings date29 Apr 2024 - 03 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    OpGen Receives Nasdaq Notice Regarding Delayed Form 10-K

    ROCKVILLE, Md., April 23, 2024 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”) announced today that it received a notice from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) due to the Company not filing its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the “Form 10-K”). Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely file all periodic reports with th

  • GlobeNewswire

    OpGen Announces Acquisition of Preferred Stock by David Lazar

    David Lazar invests $3 million in Preferred StockNew OpGen Board of Directors appointedDavid Lazar will take over as CEO of OpGenOpGen settles outstanding liabilities with EIB ROCKVILLE, Md., March 25, 2024 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), announced today that the Company entered into a securities purchase agreement with David E. Lazar, an experienced private investor, pursuant to which he will acquire 3,000,000 shares of Series E Convertible Preferred St

  • GlobeNewswire

    OpGen Reports Third Quarter 2023 Financial Results and Provides Business Update

    Total revenue for the first nine months of 2023 was approximately $2.35 million compared to approximately $1.89 million in the first nine months of 2022Implemented certain cash management initiatives, including restructuring U.S. operations by reducing headcount during the third quarter of 2023Signed preferred stock purchase agreement with a potential strategic investor in October 2023Entered into a warrant inducement agreement with an institutional investor in October 2023Subsidiaries Curetis G